# SANA — slm-full-cpu

## Metadata

ticker: SANA
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: b6a006e5535e066058b727a81b4356416ce59925612c16ea9bc2b5a6a20d76a4
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 530, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 162.542, "latency_s_total": 162.542, "parse_failure": 0, "prompt_tokens": 2059, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 438, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 150.856, "latency_s_total": 150.856, "parse_failure": 0, "prompt_tokens": 2048, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 129, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 45.207, "latency_s_total": 45.207, "parse_failure": 0, "prompt_tokens": 582, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 121, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 38.211, "latency_s_total": 38.211, "parse_failure": 0, "prompt_tokens": 576, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 180, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 74.027, "latency_s_total": 74.027, "parse_failure": 0, "prompt_tokens": 512, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 116, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 59.793, "latency_s_total": 59.793, "parse_failure": 0, "prompt_tokens": 612, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 822, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 122.028, "latency_s_total": 122.028, "parse_failure": 0, "prompt_tokens": 1474, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "SANA",
  "company_name": "Sana Biotechnology, Inc.",
  "current_price": 2.89,
  "currency": "USD",
  "market_cap": 865152256.0,
  "forward_pe": -5.206176,
  "week_52_high": 6.55,
  "week_52_low": 2.61,
  "net_income": -211822000.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-03",
    "summary": "Item 1A. Ris k Factors. Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Annual Report, including our financial statements and related notes included elsewhere in this Annual Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect o"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "Item 1A. Ri sk Factors Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all of the other information contained in this Quarterly Report, including our financial statements and related notes included elsewhere in this Quarterly Report, before making an investment decision. The risks described below are not the only ones we face. Many of the following risks and uncertainties are, and will continue to be, exacerbated by any worsening of the global geo-political, business, and economic environment. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely aff"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filing for ticker SANA, the key takeaways regarding risk factors and business outlook include:

**1. Unproven Technology and Development Risks**
*   The company’s *ex vivo* and *in vivo* cell engineering platforms rely on novel technologies that are unproven and may not result in approvable or marketable products.
*   There are no FDA-approved therapeutics derived from pluripotent stem cells (PSCs) or utilizing the company’s fusogen technology.
*   Scientific evidence supporting these platforms is preliminary and limited, making it difficult to predict development timelines, costs, and regulatory approval outcomes.

**2. Clinical and Preclinical Uncertainties**
*   Testing is inherently unpredictable, particularly for novel technologies. Results from animal models or preclinical cell lines may not accurately predict safety and efficacy in humans.
*   The company has not tested its platforms on all cell types or microenvironments, and results may not translate across different contexts.
*   Current gene editing approaches use novel reagents that may have unanticipated or undesirable effects.
*   There is limited understanding regarding safety and efficacy for certain indications, such as autoimmune diseases.

**3. Regulatory and Manufacturing Challenges**
*   The company may face significant challenges in creating appropriate models and assays to evaluate the safety and purity of its product candidates.
*   The use of novel manufacturing reagents and materials could have unknown effects on safety, efficacy, or manufacturability, potentially affecting multiple programs and causing delays.
*   Unexpected differences in product performance across indications may require changes to manufacturing processes or clinical development plans, leading to additional time and resource expenditures.

**4. Financial and Operational Risks**
*   There is substantial doubt as to the company’s ability to continue as a going concern.
*   The company requires additional funding to finance operations. Failure to raise capital when needed could force delays, reductions, or eliminations of product development or commercialization efforts.
*   Success depends on retaining key personnel and recruiting qualified staff, as well as managing growth effectively to avoid operational disruption.
*   The company may not realize the benefits of acquired or in-licensed technologies or strategic relationships.

**5. Forward-Looking Statements**
*   Statements regarding future events are based on current expectations and estimates but are subject to significant uncertainties.
*   Actual results may differ materially from those expressed or implied by forward-looking statements due to various risk factors.
*   The company does not undertake an obligation to publicly update these statements.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology:** The company’s ex vivo and in vivo cell engineering platforms are based on novel technologies that are unproven and may not result in approvable or marketable products. There is substantial doubt regarding the feasibility of developing therapeutic treatments based on these platforms, as scientific evidence is preliminary and limited.
*   **Regulatory and Development Uncertainty:** Preclinical and clinical testing is inherently unpredictable, particularly for novel technologies. Results from animal models or preclinical assays may not accurately predict safety and efficacy in humans. Additionally, there are no FDA-approved therapeutics derived from pluripotent stem cells or utilizing the company’s fusogen technology.
*   **Product Candidate Failure:** If the company is unable to successfully identify, develop, and commercialize product candidates, or experiences significant delays, its business, financial condition, and results of operations will be materially adversely affected.
*   **Going Concern and Funding Needs:** There is substantial doubt as to the company’s ability to continue as a going concern. The company requires additional funding to finance operations; failure to raise capital when needed could force the delay, reduction, or elimination of product development programs or commercialization efforts.
*   **Strategic and Licensing Risks:** The company may not realize the benefits of acquired or in-licensed technologies, nor may it successfully enter into or realize benefits from new strategic relationships.
*   **Operational and Personnel Risks:** The company’s growth depends on retaining key personnel and recruiting qualified staff. Additionally, the company may encounter difficulties in managing growth, including expanding development and regulatory capabilities, which could disrupt operations.
*   **Safety and Manufacturing Challenges:** The company may face challenges in creating appropriate models and assays to evaluate safety and purity. The use of novel manufacturing reagents and materials may have unknown or unanticipated effects on safety, efficacy, or manufacturability, potentially affecting multiple programs.
*   **Indication-Specific Variability:** Product candidates may reveal unexpected differences in safety or efficacy when developed for different indications compared to other candidates using the same technologies, potentially requiring changes to manufacturing or clinical development plans.

## Pre-written sections (judge input)

### Financial Health

Sana Biotechnology, Inc. (SANA) is currently trading at $2.89, reflecting a market capitalization of approximately $865.2 million. The company reports a negative forward P/E ratio of -5.21 and a profit margin of 0.0%, driven by a net income loss of $211.8 million. These metrics indicate that Sana is not yet profitable and remains in a high-risk, pre-revenue or early-stage growth phase typical of biotechnology firms. Investors should note the significant financial losses as the company continues to face substantial operational risks.

### Recent Developments

Sana Biotechnology has filed its 2026 Annual Report (10-K) and subsequent Quarterly Report (10-Q), with the latter filed on August 10, 2026. These filings reiterate significant risk factors, highlighting that adverse global geopolitical and economic conditions could materially and adversely affect the company’s operations. Investors should note that the company continues to report a net loss, with a negative forward P/E ratio indicating ongoing profitability challenges. Consequently, recent regulatory submissions serve primarily as risk disclosures rather than indicators of near-term operational breakthroughs.

### SEC Filing Highlights
Sana Biotechnology faces significant risks as its novel *ex vivo* and *in vivo* cell engineering platforms remain unproven, with no FDA-approved therapeutics derived from its pluripotent stem cell or fusogen technologies. The company highlights substantial doubt regarding its ability to continue as a going concern, emphasizing the critical need for additional funding to sustain operations and avoid delays in product development. Furthermore, clinical and manufacturing uncertainties persist, as preliminary scientific evidence and untested cell types make it difficult to predict safety, efficacy, and regulatory approval outcomes.

### Risk Factors

*   **Unproven Technology and Scientific Feasibility:** The company’s ex vivo and in vivo cell engineering platforms are based on novel, unproven technologies with preliminary scientific evidence, creating substantial doubt regarding the feasibility of developing approvable or marketable therapeutic treatments.
*   **Regulatory Uncertainty and Product Failure:** There are no FDA-approved therapeutics derived from pluripotent stem cells or utilizing the company’s fusogen technology; inherent unpredictability in preclinical and clinical testing, combined with the risk of significant development delays or failures, could materially adversely affect the business.
*   **Going Concern and Funding Needs:** There is substantial doubt regarding the company’s ability to continue as a going concern, as it requires additional capital to finance operations; failure to raise funds when needed could force the delay, reduction, or elimination of product development and commercialization efforts.

## Audited (Exec Summary + Outlook)

### Executive Summary
Sana Biotechnology is a pre-revenue biotechnology firm developing novel *ex vivo* and *in vivo* cell engineering platforms, currently trading at $2.89 with a market capitalization of approximately $865.2 million. The stock is notable for its high-risk profile, characterized by a net income loss of $211.8 million and substantial doubt regarding its ability to continue as a going concern without additional capital. The single most important near-term variable is the company’s ability to secure sufficient funding to sustain operations and avoid delays in its unproven product development pipeline.

### Outlook
The directional outlook for Sana Biotechnology is cautiously cautious, defined primarily by existential funding risks rather than near-term commercial potential. Key variables to monitor include the company’s cash runway, the timing and terms of any potential capital raises, and progress in validating its scientific platforms through preclinical or early-stage clinical data. The thesis would be strengthened by evidence of successful platform validation or a clear path to sustainable financing, while it would be significantly weakened by further dilution, inability to secure capital, or setbacks in demonstrating the feasibility of its unproven technologies.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $2.89"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"current_price": 2.89` for ticker SANA.

---

CLAIM: "market capitalization of approximately $865.2 million"
LABEL: SUPPORTED
REASON: The raw source data lists `"market_cap": 865152256.0`, which rounds to approximately $865.2 million.

---

CLAIM: "net income loss of $211.8 million"
LABEL: SUPPORTED
REASON: The raw source data lists `"net_income": -211822000.0`, which rounds to a loss of $211.8 million.

---

CLAIM: "substantial doubt regarding its ability to continue as a going concern without additional capital"
LABEL: SUPPORTED
REASON: The SEC Filing Highlights and RAG sections explicitly state "There is substantial doubt as to the company's ability to continue as a going concern" and that "The company requires additional funding to finance operations."

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All statements are qualitative and directional (e.g., "cash runway," "timing and terms," "successful platform validation," "clear path to sustainable financing"). There are no numerical claims to audit in this section.

---

**SUMMARY**

All four auditable quantitative claims in the Executive Summary are **SUPPORTED**. The Outlook section contains no quantitative or specifically enumerable forward-looking figures requiring audit entries.
